Cover Image
市場調查報告書

Relmada Therapeutics, Inc.:產品平台分析

Relmada Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 285615
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Relmada Therapeutics, Inc.:產品平台分析 Relmada Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年10月14日 內容資訊: 英文 29 Pages
簡介

Relmada Therapeutics, Inc. 正在開發·銷售臨床階段的管理慢性及神經性疼痛產品。該公司主要販售止痛藥和抗關節炎藥,同時也致力於開發癌症和肌肉骨骼障礙,末梢神經病變的慢性止痛藥。

本報告提供Relmada Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Relmada Therapeutics, Inc.的基本資料

  • Relmada Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Relmada Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Relmada Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Relmada Therapeutics, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Relmada Therapeutics, Inc.:藥物簡介

  • levorphanol tartrate ER
  • dextromethadone
  • buprenorphine hydrochloride ER
  • mepivacaine hydrochloride

Relmada Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Relmada Therapeutics, Inc.:最近的開發平台趨勢

Relmada Therapeutics, Inc.:暫停中的計劃

Relmada Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07662CDB

Summary

Global Markets Direct's, 'Relmada Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Relmada Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Relmada Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Relmada Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Relmada Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Relmada Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Relmada Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Relmada Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Relmada Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Relmada Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Relmada Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Relmada Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Relmada Therapeutics, Inc. Snapshot
    • Relmada Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Relmada Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Relmada Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Relmada Therapeutics, Inc. - Pipeline Products Glance
    • Relmada Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Relmada Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Relmada Therapeutics, Inc. - Drug Profiles
    • levorphanol tartrate ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REL-1017
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mepivacaine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Relmada Therapeutics, Inc. - Pipeline Analysis
    • Relmada Therapeutics, Inc. - Pipeline Products by Target
    • Relmada Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Relmada Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Relmada Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Relmada Therapeutics, Inc. - Recent Pipeline Updates
  • Relmada Therapeutics, Inc. - Dormant Projects
  • Relmada Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Relmada Therapeutics, Inc., Key Information
  • Relmada Therapeutics, Inc., Key Facts
  • Relmada Therapeutics, Inc. - Pipeline by Indication, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Relmada Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Relmada Therapeutics, Inc. - Phase II, 2015
  • Relmada Therapeutics, Inc. - Phase I, 2015
  • Relmada Therapeutics, Inc. - Preclinical, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Target, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Relmada Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Relmada Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Relmada Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Relmada Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Relmada Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Relmada Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Relmada Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top